BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Area of Science:

• Oncology
• Genetics
• Genomic Medicine

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate below 9% despite advances in treatment.
• Genomic studies reveal that germline mutations in BRCA and PALB2 genes occur in 5-9% of PDAC patients, leading to homologous repair deficiency (HRD).

Purpose of the Study:

• To review current and emerging biomarkers for HRD in PDAC.
• To discuss treatments for HRD-positive PDAC, including PARP inhibitors and cytotoxic agents.
• To highlight the clinical implications of HRD and the recommendation for universal germline testing in PDAC.

Main Methods:

• Review of existing literature on PDAC genomics, HRD, and treatment strategies.
• Analysis of the role of germline mutations (BRCA, PALB2, ATM, RAD51) and "BRCAness" in PDAC.
• Evaluation of therapeutic approaches targeting DNA repair pathways.

Main Results:

• HRD-positive PDAC shows increased susceptibility to DNA-damaging agents like platinum salts and topoisomerase inhibitors.
• PARP inhibitors represent an effective non-cytotoxic treatment for HRD-PDAC.
• Germline mutations in DNA repair genes and somatic mutations contribute to HRD phenotypes.

Conclusions:

• Germline testing for HRD in PDAC is clinically significant and now recommended universally.
• Targeting HRD pathways offers promising therapeutic strategies for improving PDAC patient outcomes.
• Further research is needed to address challenges in HRD biomarker identification and treatment optimization.